Schedule 13D ownership disclosure
Fate Therapeutics Inc
Common Stock, $0.001 par value per share · CUSIP: 31189P102
Event date: 2024-12-20
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Redmile Group, LLCReported CIK 0001425738
Shares: 17,816,634.00 · Class: 14.9%
- Jeremy C. GreenReported CIK 0001650527
Shares: 17,816,634.00 · Class: 14.9%
- RedCo II Master Fund, L.P.Reported CIK 0001921783
Shares: 9,787,689.00 · Class: 8.5%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001104659-24-131793
- Form type
- SCHEDULE 13D/A
- Filer
- FATE THERAPEUTICS INC
- CIK
- CIK 1434316
- Filed
- Dec 26, 2024
- Reporting period
- Dec 20, 2024
- Description
- Schedule 13D beneficial ownership